# Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

> **NCT05123040** · PHASE1,PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 10 (actual)

## Conditions studied

- Acute-graft-versus-host Disease

## Interventions

- **DRUG:** Ruxolitinib 10 MG Oral Tablet
- **DRUG:** hCG
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT05123040
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-05
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-02-27
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor terminated financial support
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123040, "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05123040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*